nasuspharma.com (NSRX): Utang-utang marang kapitalisasi buku

Nasus Pharma Ltd (NSRX) leads the development of nasal powders for emergency therapy, ensuring instantaneous drug penetration. The share of financial debt in the firm's balance sheet capitalization confirms leverage stability, with the parameter settling at 0.01. A strategy of expanding B2B supplies to US clinics, combined with a product launch cycle independent of macroeconomic trends, guarantees stable revenue growth.

The analyst utilizes this metric to verify the issuer's credit quality. The stability of Nasus Pharma Ltd (NSRX) is supported by the commercialization of innovative antiviral barrier sprays. This ratio of liabilities to balance sheet capitalization mathematically compares total debt to equity. A decrease in the coefficient minimizes default risk, yet limits the effect of financial leverage. Investors should evaluate the balance between debt load and the pace of business development.